Cargando…

B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis

BACKGROUND: Approximately 30% of adult patients with immunoglobulin A (IgA) nephropathy (IgAN) or IgA vasculitis with nephritis (IgAVN) develop end-stage renal disease during long-term follow-up. In particular, patients with nephritic–nephrotic syndrome have an increased risk of rapid progression. C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lundberg, Sigrid, Westergren, Emelie, Smolander, Jessica, Bruchfeld, Annette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	B-Cell Depletion in Glomerulopathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469569/ https://www.ncbi.nlm.nih.gov/pubmed/28638602 http://dx.doi.org/10.1093/ckj/sfw106

Ejemplares similares

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

The size of palatine tonsils cannot be used to decide the indication of tonsillectomy for IgA nephropathy
por: Sato, Mitsuhiro, et al.
Publicado: (2017)

Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy
por: Jullien, Perrine, et al.
Publicado: (2017)

C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome
por: Lloyd, Isaac E., et al.
Publicado: (2016)

MMP2 and MMP9 associate with crescentic glomerulonephritis
por: Phillips, Tessa M., et al.
Publicado: (2017)

Nephrotic syndrome due to minimal change disease secondary to spider bite: clinico-pathological case of a non-described complication of latrodectism
por: Méndez, Gonzalo P., et al.
Publicado: (2017)

Ofatumumab treatment in lupus nephritis patients
por: Haarhaus, Malena Loberg, et al.
Publicado: (2016)

Dense deposit disease: a greatly increased biopsy incidence in India versus the USA
por: Prema, K S Jansi, et al.
Publicado: (2019)

Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy
por: Bharati, Joyita, et al.
Publicado: (2018)

Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series
por: McAdoo, Stephen P., et al.
Publicado: (2016)

14. A great mimicking vasculitis
por: Black, Simon, et al.
Publicado: (2018)

11. Vasculitis in a patient with intracranial myeloma
por: El-Ghazali, Shawki, et al.
Publicado: (2018)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
por: Thiel, Jens, et al.
Publicado: (2011)

Immunoglobulin A vasculitis nephritis: Current understanding of pathogenesis and treatment
por: Amatruda, Michela, et al.
Publicado: (2023)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
por: Dwojak, M, et al.
Publicado: (2015)

Bevacizumab-induced immunoglobulin A vasculitis with nephritis: A case report
por: Endo, Yoko, et al.
Publicado: (2019)

Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report
por: Zhang, Fan, et al.
Publicado: (2022)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

The COVID-19 Epidemic: Management and Outcomes of Hemodialysis and Peritoneal Dialysis Patients in Stockholm, Sweden
por: Smolander, Jessica, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy
por: Cao, Shugang, et al.
Publicado: (2023)

Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children
por: Zhong, Xuhui, et al.
Publicado: (2022)

Clinical validation of immunoglobulin A nephropathy diagnosis in Swedish biopsy registers
por: Jarrick, Simon, et al.
Publicado: (2017)

Evaluation of the Oxford classification in immunoglobulin A vasculitis with nephritis: a cohort study and meta-analysis
por: Yu, Bingxin, et al.
Publicado: (2020)

Imbalanced Th17/Treg in peripheral blood of adult patients with immunoglobulin A vasculitis nephritis
por: Xue, Xue, et al.
Publicado: (2021)

Comparative proteomic analysis of glomerular proteins in IgA nephropathy and IgA vasculitis with nephritis
por: Kaga, Hajime, et al.
Publicado: (2023)

Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis
por: Shah, Shivani, et al.
Publicado: (2017)

Diagnostic Utility of Galactose-Deficient Immunoglobulin A1 Immunostaining in the Differentiation of Lupus Nephritis and Immunoglobulin A Nephropathy
por: Bu, Lihong, et al.
Publicado: (2021)

C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study
por: Bruchfeld, Annette, et al.
Publicado: (2022)

Successful treatment of tubulointerstitial nephritis in immunoglobulin G4-related disease with rituximab: A case report
por: Eroglu, Eray, et al.
Publicado: (2019)

Genetic Risk Factors in Lupus Nephritis and IgA Nephropathy – No Support of an Overlap
por: Vuong, Mai Tuyet, et al.
Publicado: (2010)

Impfungen unter Ofatumumab gelingen
por: Facharztmagazine, Redaktion
Publicado: (2023)

Serum TNF-α Level Is Associated with Disease Severity in Adult Patients with Immunoglobulin A Vasculitis Nephritis
por: Wu, Haiting, et al.
Publicado: (2020)

Safety Evaluation of COVID-19 Vaccine in Patients With IgA Nephropathy or IgA Vasculitis Nephritis
por: Zan, Jincan, et al.
Publicado: (2022)

Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children
por: Lv, Yan, et al.
Publicado: (2023)

Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis
por: Li, Qianqian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ggj9674om7h7tuk5dbeqkjju52